Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Improved survival in patients with multiple myeloma over time: A retrospective single-center study focusing on patients aged 80 years and above

View Full Paper
Ask AI
Bookmark
Share

Authors

MIMasaki IinoTMTakahiro MikawaMYMasanori Yoshikawa

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows survival benefit from therapeutic agents in patients aged 80+, highlighting comorbidity challenges.

Key Points

  • To evaluate the survival benefits of novel therapeutic agents for multiple myeloma in patients aged 80 years and older.
  • Retrospective analysis of overall survival for 300 patients diagnosed with multiple myeloma
  • Patient cohorts divided by treatment era: early (2007-2014) and later (2015-2023)
  • Kaplan–Meier method for overall survival estimation; log-rank test for comparisons
  • Cumulative incidence of MM-related and non-MM-related deaths assessed using Gray's test
  • 2-year overall survival improved significantly from 51.8% to 73.7% from early to later era
  • MM-related mortality decreased from 26.2% to 12.8% at 2 years
  • Non-MM-related mortality declined from 21.9% to 13.5%
  • In patients aged ≥80 years, MM-related mortality improved but non-MM-related mortality remained unchanged

Cite This Study

Iino et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7behttps://doi.org/10.1182/blood-2025-2203
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of Treatment2024 · 1 citations
  2. 2Main biologic and clinic features at presentation and treatment results in very elderly patients (> 75 Years) with  Multiple myeloma: A multicentric experience2025
  3. 3Age-centric insights: A single-center analysis of clinical presentation, treatment approaches, and outcomes in multiple myeloma patients across different age groups.2026
  4. 4The future mortality trends in multiple myeloma (SEER analysis 2000–2030).2026
  5. 5P54 | EVOLVING OUTCOMES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE: 30-YEARS SINGLE CENTER EXPERIENCE2026